Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst ...

Genmab AS (GMAB) reports a 19% revenue increase and a 56% rise in operating profit, showcasing strong financial performance ...

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...

But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. There are plenty of strategies for discovering value stocks, but we have ...

Genmab ( ($GMAB) ) has issued an update. On August 12, 2025, Genmab A/S announced a capital increase of 4,563 shares following the exercise of ...

GMAB stands above ACAD thanks to its solid earnings outlook, and based on these valuation figures, we also feel that GMAB is the superior value option right now.

Genmab's (GMAB) stock gains as its lymphoma drug epcoritamab developed with AbbVie (ABBV) succeeds in a Phase 3 lymphoma ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Genmab A/S (NASDAQ:GMAB) is one of the Best Extremely Profitable Stocks to Buy Right Now. On July 16, Genmab A/S (NASDAQ:GMAB) announced new sales figures for DARZALEX as of the second quarter of ...

Genmab (GMAB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Danish biotech Genmab (Nasdaq: GMAB) and US partner AbbVie (NYSE: ABBV) have reported a decisive win in a Phase III study of ...

Danish biotech Genmab (Nasdaq: GMAB) posted second-quarter revenue of $925 million, up 19% from a year earlier, driven by ...